AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Polyrizon shares surge 118.76% intraday after reporting preclinical data showing longer adhesion time for naloxone hydrogel and completing manufacturing scale-up for 2026 trials.
ByAinvest
Thursday, Dec 4, 2025 10:25 am ET1min read
Polyrizon surged 118.76% intraday, driven by the release of preclinical data showing its proprietary naloxone hydrogel demonstrated significantly longer adherence time compared to commercial products (p<0.0001) and the successful completion of a manufacturing scale-up milestone for its PL-14 nasal spray platform, enabling large-scale production for 2026 clinical trials.
The company announced on December 3 that its naloxone hydrogel showed statistically significant (p<0.0001) extended adherence on an ex vivo rabbit nasal mucosa model compared to existing naloxone sprays, supporting potential for prolonged nasal deposition. On December 2, it also announced completing the PL-14 nasal spray platform's manufacturing scale-up, transitioning from lab-scale to large-scale production while validating formula quality stability, ensuring compliance with U.S. and European standards for 2026 clinical trials.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet